Barrett's-related esophageal adenocarcinoma: is chemoprevention a potential option?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11513166.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Review the rationale behind secondary prevention of Barrett's related esophageal adenocarcinoma and critically appraise the emerging literature regarding prevention of neoplasia in Barrett's esophagus with antisecretory and/or cyclo-oxygenase inhibition therapy. The existing English language literature regarding secondary cancer prevention in patients with Barrett's esophagus is reviewed and its potential clinical implications discussed. There is biologic plausibility to pursue "chemoprevention" trials with antisecretory and/or cyclo-oxygenase inhibition therapy in patients with Barrett's esophagus. Chemoprevention trials using potent antisecretory therapy coupled with cyclo-oxygenase 2 inhibition are warranted and may provide a means of decreasing the occurrence of cancer and cancer-related mortality in this disease.
Medical subject headings
- Adenocarcinoma
- Anti-Ulcer Agents
- Barrett Esophagus
- Cyclooxygenase Inhibitors
- Enzyme Inhibitors
- Esophageal Neoplasms